Gene interactions and pathways from curated databases and text-mining
Curr Opin Investig Drugs 2010, PMID: 20496258

Novel inhibitors of mTORC1 and mTORC2.

Bhagwat, Shripad V; Crew, Andrew P

The PI3K/Akt/mTOR pathway is frequently activated in human cancers, and mTOR is a clinically validated target for therapeutic intervention in this pathway. The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt, combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1)-directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2. This review describes progress in the identification of selective and novel inhibitors of mTORC1/2, focusing on the profile of inhibitors that are in clinical development.

Diseases/Pathways annotated by Medline MESH: Neoplasms
Document information provided by NCBI PubMed

Text Mining Data

Akt — mTOR complex 2 (mTORC2): " The discovery of the involvement of rapamycin-insensitive mTOR complex 2 (mTORC2) in the activation of Akt , combined with the limited clinical antitumor activity of mTOR complex 1 (mTORC1) directed rapamycin analogs, have led to the discovery of ATP-competitive selective inhibitors of the mTOR kinase that inhibit the function of both mTORC1 and mTORC2 "

Manually curated Databases

No curated data.